The biosimilar market in China has some similarities to the one in the United States. Still, there are some major differences. First, to get a biosimilar developed and approved takes much longer in the US than in China. According to Huiya Wu, JD, an intellectual property lawyer from Goodwin, biosimilar development alone takes around 7 to 8 years in the US but could take as little as 5 years in China. Read The Center for Biosimilars article here.
In The Press February 07, 2021